all results the our a summary year-end Good hope earnings release and would Lisa. with everyone. call. XXXX for we to safe Yesterday, of issued update are press after like to you and We closed, and our business you Thank welcome XXXX. update business financial well. market morning you We a
XX-K. Form of on documents reports diamedica.com. annual Kellen our filed Chief Officer, Investors our section also found and be Media With is Medical the Scott Dr. our Both in Financial today We can at Officer, Harry Chief our me Alcorn. and here website
proud the which accomplished DiaMedica set out we some items ambitious ago. am our each has of goals of a I for year outlined team XXXX.
Phase initiated DMXXX disease. X of in a patients kidney step in a Specifically, understanding kidney with study the we profile with completed on disease, impact Xb our planned, chronic Phase chronic preparing disease for pharmacokinetics key study the in and subjects and kidney for
assembled development we truly Second, guide board program. disease kidney world-class our chronic to a clinical advisory
and Phase advisory hypertensive important participants with Americans working disease with initiated non-diabetic. kidney X will our we an are planned disease kidney trial, Third, IgA trial chronic we Nephropathy and by which caused in board, study African that chronic and
enrollment our in in ischemic enlarged completed we stroke. study Lastly, REMEDY acute
balance attract equity this were we of pubic to funds strengthened in small accomplishments, the a of which of complete offering these of year, able because believe our and a interest We couple biotech sheet. February
the impacts with to even market capital XXXX. volatility challenging operations to the funding caused the we end exposed with we environment and Coronavirus have potential our complete As to COVID-XX. along less the current are a Therefore, by through current of our outbreak studies, related adverse result,
potential stroke. to accomplishments, from disease DMXXX with patients on XXXX. have remains the suffering the acute committed of significant development chronic entire in advancing ischemic DMXXX the replete clinical holds impact team our kidney While to and
cautiously from DMXXX during see We as Phase become sharing excited look to results X and they the are optimistic available. XXXX we to forward and clinical data
Now let our more in touch detail. on programs clinical us
study ischemic with with respect in stroke. subjects REMEDY acute our to First,
disclosed for We and last XX in Phase participants. enrollment efficacy of previously the DMXXX that explore DMXXX. or the include AIS therapeutic of of The Modified enrollment Barthel have the and tolerability assess X Rankin ischemic final of safety Health potential Scale, National the completed to standard participants functional is and stroke, October also designed measurements was stroke Remedy of study Scale to markers Index. the of the was this from study acute endpoints and suffering treatment a Stroke Institutes
C-reactive assessed inflammation such evaluate We like will biomarkers, of at measures including multiple also throughout These points as markers are days the post-stroke. study, multiple plasma-based protein. XX
the duration of in also the kidney calculating estimated disease, the rate study. work over the and glomerular interest potential between renal and because addition, of be of the we In our measured function community participants ever-increasing medical and will for the at links looking vascular filtration kidney the by space
unrelated weeks analyze to and staffing slowed with due topline the by will of have accuracy the few organization issues files, research and process last our this are study the COVID-XX. we statistical files clinical have completeness by completed and we and then has and we the the These January to analysis follow-up was the verify announcing contract for Unfortunately, analysis. research compiling our or from Once we late The results. database results. will participant been in waiting XXXX the contract follow SAP along visit advisors organization those with been
planned as XXXX. for results We then which is release and soon possible review early work aggressively topline QX the to and will as
with postponement study results. the alternatives evaluating Conference to XXXX, for are from May the releasing we full European Additionally, of Stroke November
our X turn which Next, REDUX enrolling is Phase to CKD let cohorts. participants study, us in two
The previously who biopsy by on is the hypertensive are first cohort on African second Americans with cohort confirmed focused participants and IgA not is Nephropathy, focusing diabetic.
target is dose as and treated Our The standard estimated rate safety referred XX markers. per cohort will enrollment endpoints will primary tolerability participants weeks XX participants glomerular at filtration with and and along albuminuria, also approximately eGFR for the two be levels. to be
in study and We past continue enroll subjects in to enrollment weeks. two the this REDUX the includes
level have slower said, chronic but enrollment This diabetic. finding screen expected. That in are cohort a with that failures has higher of related subject been to disease, not primarily experienced we than has individuals African-American where been the kidney
recruitment We of candidates. have and identification, and been participants available of screening increased clinical the from our XX the the XX we improve sites of to to pool study study recently sites to expand working number with
of of virus this the spite effect in adverse recent have enrollment, mitigate in recruitment. to recent taken U.S. on to However, appear COVID-XX and outbreak the subject spread a the measures
approach here, for of maximize the principle home consistent design approach various majority We For with originally authorities. to compliance with Today, participant I the out by we is treatments. that in social point registered visits the that make subject comfort context our study to nurses to recommended of take distancing government the some for original treatment want this protocol. provided chose this
of don't sites U.S. clinical the disrupt already we out subjects across expect XX spread that are today, treatment the COVID-XX The will enrolled. widely of clinical As
are to XX study others yesterday, screen of and the of to open the XX to remain patients continuing and intend sites while recruit continue enroll As subjects.
basis on week. last new We This did change have day-to-day patients could and state-by-state. a enrolled
been that participants service to nursing safety the procedures have diligently protect study has providers to and Our of clinical in home ensure personnel. study and place working sites team clinical also
visit first to treatment to the to impact home need to the minimize In just of of addition, office would requirement participation. allow doctor's social the This study or to to and subjects the isolation steps further clinic performed the travel for are we taking the on in subject's reduce be screening study limit clinic. subject's the subject to day
With to of just Review the the visits Board measures outbreak combating also could extent of recent drug. of initial COVID-XX knows to may the is ultimately taken. Obviously, and minimize dosing the acceptance of patient U.S. still the the the one no called clinic IRB process that we Institutional called early in changes, be the
of the the comfortable We the feel COVID-XX safety a on situation, continue minimum. and commit clinical we a the conditions allow. light to additional interim trial availability evolving monitor integrity participants, as We protecting focused Instead, providing no best projection our trial impact to we to of of will on results. evaluate to and keep the culminating but topline risk of studies, longer of in adhering providing information remain for rapidly practices
summary provide to With that, turn I the for call XXXX. of over to results financial our will now Scott a
